Fineimmu announced that it has received nearly CNY 100,000,000 in its pre-series A round of funding led by Huafang Investment on August 3, 2022. The transaction included participation from Yabao Pharmaceutical Group Co., Ltd and Panacea Venture Management Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6.13 CNY | +0.49% | -3.01% | -11.16% |
1st Jan change | Capi. | |
---|---|---|
-11.16% | 609M | |
+15.91% | 41.97B | |
+22.40% | 22.34B | |
+18.48% | 15.25B | |
+16.12% | 14B | |
+45.12% | 12.06B | |
-0.05% | 6.79B | |
-9.58% | 6.8B | |
-8.87% | 5.73B | |
+14.18% | 5.49B |
- Stock Market
- Equities
- 600351 Stock
- News Yabao Pharmaceutical Group Co., Ltd
- Fineimmu announced that it has received CNY 100 million in funding from Yabao Pharmaceutical Group Co., Ltd, Panacea Venture Management Co., Ltd. and another investor